Genocea Biosciences (NASDAQ:GNCA – Get Rating) and Aziyo Biologics (NASDAQ:AZYO – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.
This is a breakdown of current ratings and recommmendations for Genocea Biosciences and Aziyo Biologics, as reported by MarketBeat.com.Get Genocea Biosciences alerts:
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Genocea Biosciences presently has a consensus price target of $3.00, suggesting a potential upside of 26,685.71%. Aziyo Biologics has a consensus price target of $12.00, suggesting a potential upside of 83.21%. Given Genocea Biosciences' higher possible upside, analysts clearly believe Genocea Biosciences is more favorable than Aziyo Biologics.
Risk & VolatilityGenocea Biosciences has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Aziyo Biologics has a beta of -0.68, meaning that its share price is 168% less volatile than the S&P 500.
This table compares Genocea Biosciences and Aziyo Biologics' net margins, return on equity and return on assets .
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Genocea Biosciences and Aziyo Biologics' revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Genocea Biosciences||$1.64 million||0.40||-$33.20 million||($0.61)||-0.02|
|Aziyo Biologics||$47.39 million||1.87||-$24.83 million||($2.46)||-2.66|
Aziyo Biologics has higher revenue and earnings than Genocea Biosciences. Aziyo Biologics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
59.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 88.6% of Aziyo Biologics shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 39.9% of Aziyo Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aziyo Biologics beats Genocea Biosciences on 8 of the 14 factors compared between the two stocks.
About Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
About Aziyo Biologics
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.